Tiziana Life Sciences announces publication of intranasal foralumab results

Tiziana Life Sciences (TLSA) announces the peer-reviewed publication of its open-label study in patients with non-active secondary progressive multiple sclerosis in Neurology Neuroimmunology & Neuroinflammation, a prestigious journal of the American Academy of Neurology.The publication, titled “Nasal Foralumab for the Treatment of Progression Independent of Relapses in Patients with Non-active Secondary Progressive Multiple Sclerosis,” details the comprehensive positive results previously announced by the Company on May 6, 2025. This marks the first study to integrate TSPO-PET imaging, proteomics, and clinical assessments in na-SPMS, highlighting nasal foralumab’s novel mechanism in addressing progression independent of relapse activity-a critical unmet need in multiple sclerosis treatment. Key Study Highlights: Ten patients with na-SPMS, progressing despite prior B-cell therapies, received nasal foralumab for at least six months. No serious or severe treatment-related adverse events occurred. All patients showed stabilization of Expanded Disability Status Scale scores; three of four treated for 12 months demonstrated improvement. Fatigue improved in six out of ten patients, as measured by the Modified Fatigue Impact Scale-a vital quality-of-life measure for MS patients. No new T2 lesions appeared on MRI. TSPO-PET imaging revealed significant reductions in microglial activation at three and six months. Single-cell RNA sequencing demonstrated sustained increases in regulatory T cells and TGFbeta expression, supporting induction of regulatory immunity.